CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing CD19 biological mechanisms, diagnostic applications, and preclinical/early clinical therapeutics.
PubMed 8528044 · doi:10.3109/10428199509059636
What was done
The authors reviewed the expression pattern of the CD19 antigen across normal B-lymphocyte differentiation and neoplastic hematologic conditions, alongside its utility in flow cytometry diagnosis and emerging immunotherapies (including monoclonal antibodies and immunotoxins) for acute lymphocytic leukemia and non-Hodgkin's lymphoma.
What was found
No quantitative data, sample sizes, or effect estimates are reported in the abstract. Qualitatively, CD19 is expressed starting at B-lineage commitment through mature B cells, down-regulated in plasma cells, absent on pluripotent stem cells, and retained on transformed B cells as well as a subset of acute myelogenous leukemias. Anti-CD19 immunotoxins demonstrated activity in vitro, in animal models, and in Phase I trials, with anti-CD19 antibodies also capable of inducing apoptosis and cell cycle arrest via receptor-mediated signaling.
Why it matters
It summarizes the foundational biological rationale that positioned CD19 as a central diagnostic marker and therapeutic target in B-cell hematologic malignancies.
Limits
As a narrative review, it presents broad conclusions without primary numerical data, statistical comparisons, or systematic review methodology. Data regarding clinical efficacy and adverse effects in human subjects are not quantified in the abstract.
Cited by
- supports CD19 is expressed on the surface of normal healthy B cells as well as multiple types of B-cell leukemias and lymphomas.